How Biotech Startups Are Using Base Editing to Treat Genetic Disease

Base editing is a newer gene-editing technology that can change a single DNA letter without cutting the double helix. In this episode, Lucas and Luna explore how biotech startups are applying base editing to treat genetic diseases like sickle cell disease and progeria. They discuss the story of Beam Therapeutics, the first company to take a base editor into clinical trials, and contrast base editing with both traditional CRISPR and newer prime editing. The hosts break down the science behind adenine and cytosine base editors, the business of licensing foundational IP from the Broad Institute, and the regulatory path for in vivo therapies. They also touch on the ethical considerations and what this means for patients with currently untreatable conditions. Specific numbers: Beam's lead program in sickle cell disease, the estimated patient population, and the timeline for early-phase data. This episode is for anyone interested in the frontier of precision genetic medicine beyond CRISPR-Cas9. #BaseEditing #GeneEditing #BeamTherapeutics #SickleCellDisease #Progeria #DavidLiu #BroadInstitute #PrimeEditing #CRISPR #PrecisionMedicine #GeneticDisease #AdenineBaseEditor #CytosineBaseEditor #BiotechStartups #FDA #ClinicalTrials #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo